Congress passed the APMA-endorsed SUPPORT for Patients and Communities Reauthorization Act of 2025 (HR 2483), which includes an important change affecting podiatry organizations. As a direct result of APMA's advocacy efforts, the bill includes a technical fix to the DEA Medication Access and Training Expansion (MATE) Act, which allows podiatry organizations to provide mandatory training on the treatment and management of patients with substance use disorders.
The original draft legislation unintentionally excluded APMA and CPME from providing and approving training programs, which would have resulted in opioid education gaps for podiatric physicians. APMA commends Congress for their bipartisan commitment to address the opioid epidemic and ensure that podiatrists have the proper education to continue providing safe, effective pain management for foot and ankle patients.
APMA gratefully acknowledges all APMA members who advocated to ensure podiatry organizations were included as accepted providers of substance abuse education. If you would like to get involved in future advocacy, contact the Advocacy Department at advocacy@apma.org.
Be a part of our next victory by joining APMA today at www.apma.org/join!